Reference,Reference: DOI,Assay,Section,Pre-vaccine Infection,Vaccine,# Shots,Months,Host,Control,Control: NT50 Cmp,Control: NT50 GeoMean,Control: NT50 GSD,Variant,Variant: Pos,Variant: Mutations,# Results,Potency: NT50 Cmp,Potency: NT50 GeoMean,Potency: NT50 GSD,Fold Reduction: Cmp,Fold Reduction: Median
Gong21,10.1016/j.virol.2021.09.001,Pseudovirus (HIV),Figure 6,Wild Type,BNT162b2,1,1m,Human,Wild Type (B.1),=,1946.0,1.0,Beta,18,L18F + D80A + D215G + Δ242-244 + R246I + K417N + E484K + N501Y + A701V,1,=,381.0,1.0,=,5.1
Gong21,10.1016/j.virol.2021.09.001,Pseudovirus (HIV),Figure 6,Wild Type,BNT162b2,1,1m,Human,Wild Type (B.1),=,2004.0,1.0,Beta,18,L18F + D80A + D215G + Δ242-244 + R246I + K417N + E484K + N501Y + A701V,1,=,2910.0,1.0,=,0.7
Gong21,10.1016/j.virol.2021.09.001,Pseudovirus (HIV),Figure 6,Wild Type,BNT162b2,1,1m,Human,Wild Type (B.1),=,3354.0,1.0,Beta,18,L18F + D80A + D215G + Δ242-244 + R246I + K417N + E484K + N501Y + A701V,1,=,768.0,1.0,=,4.4
Gong21,10.1016/j.virol.2021.09.001,Pseudovirus (HIV),Figure 6,Wild Type,BNT162b2,1,1m,Human,Wild Type (B.1),=,4054.0,1.0,Beta,18,L18F + D80A + D215G + Δ242-244 + R246I + K417N + E484K + N501Y + A701V,1,=,1597.0,1.0,=,2.5
Gong21,10.1016/j.virol.2021.09.001,Pseudovirus (HIV),Figure 6,Wild Type,BNT162b2,1,1m,Human,Wild Type (B.1),=,7841.0,1.0,Beta,18,L18F + D80A + D215G + Δ242-244 + R246I + K417N + E484K + N501Y + A701V,1,=,376.0,1.0,=,20.9